BioCryst Pharmaceuticals | BCRX - 销售毛利



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.97B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


销售毛利 更改 日
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
BioCryst Pharmaceuticals USD 214.41M 61.36M 2026-06
Chugai Pharma JPY 237.37B 21.38B 2026-06
Daiichi Sankyo JPY 287.15B 152.68B 2026-03
DBV Technologies USD 2.77M 33.21M 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 6.8B 1.29B 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
Glaxosmithkline GBP 5.75B 2.99B 2026-03
Incyte USD 1.57B 400.89M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
Karyopharm Therapeutics USD 33.72M 1.13M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novavax USD 125.04M 76.09M 2025-12
PTC Therapeutics USD 232.94M 84.56M 2026-03
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06